Low Molecular Weight Heparin and Prevention of Postoperative Thrombosis in Abdominal Surgery

Summary

In a prospective, double-blind, randomized multicenter trial the efficacy and safety of low molecular weight heparin and unfractionated heparin were compared for the prevention of postoperative deep vein thrombosis in patients undergoing abdominal surgery. Six hundred and seventy-three patients were randomly allocated to the two prophylaxis groups; 20 of these, however, did not undergo surgery and did not receive any prophylaxis. Of the remaining 653 patients 323 received one subcutaneous injection of 3,000 anti-Xa units of low molecular weight heparin and 330 received subcutaneously 5,000 U heparin three times a day. Treatment was initiated 2 h preoperatively and continued for 7 to 10 days. The occurrence of DVT was determined by the ¹²⁵I-labelled fibrinogen uptake test and phlebography. Venous thrombosis was diagnosed in 24 of 323 patients (7.4%) treated with low molecular weight heparin and in 26 of 330 patients (7.9%) treated with low-dose heparin. DVT of proximal veins was detected in four patients of the low molecular weight heparin group and in three patients of the low-dose heparin group. During the observation period three pulmonary emboli - one fatal and two non-fatal - occurred in patients receiving prophylaxis with low-dose heparin. No pulmonary embolism was found in patients treated with low molecular weight heparin. Both prophylactic schemes were well tolerated. Intra-and postoperative blood loss, incidence of wound hematoma, frequency and volume of intra- and postoperative blood transfusion were similar in both groups with a slight advantage for the low molecular weight heparin group. The results of this trial show that the investigated low molecular weight heparin is at least as effective and safe as low-dose heparin in preventing deep vein thrombosis in patients undergoing elective abdominal surgery.

• References

• 1 Hellstem P, Kiehl R, von Blohn G, Kohler M, Meierhenrich U, Wenzel E. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals. Thromb Haemostas 1986; 56: 225-228
• 2 Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
• 3 Adolf J, Knee H, Roder JD, van de Flierdt E, Siewert JR. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Abdominalchirurgie. Dtsch Med Wschr 1989; 114: 48-53
• 4 European Fraxiparin Study (EFS) Group Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-1063
• 5 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicenter trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
• 6 Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PG. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. Thromb Haemostas 1986; 56: 243-246
• 7 Sasahara AA, Koppenhagen K, Haring R, Welzel D, Wolf H. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis. Br J Surg 1986; 73: 697-700
• 8 Kakkar W, Nicolaides AN, Renney JTG, Fried JR, Clarke MB. ¹²⁵I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis. Lancet 1970; i: 540-542
• 9 Haas S, Stemberger A, Fritsche H-M, Welzel D, Wolf H, Lechner F, Bliimel G. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneim-Forsch/Drug Res 1987; 37 (II), No. [phone]
• 10 Hauck WW, Anderson S. A proposal for interpreting and reporting negative studies. Stat Med 1986; 5: 203-209
• 11 Kakkar W, Howe GT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg - is there a “high risk” group. Am J Surg 1970; 120: 527-530
• 12 Wolf H, Welzel D. Regionalanasthesie bei gleichzeitiger Throm-boseprophylaxe mit niedermolekularem Heparin. Perfusion 1991; 7: 229-232
• 13 Wolf H, Encke A, Haas S, Welzel D. Comparison of efficacy and safety of Sandoz low molecular weight heparin and unfractionated heparin: interim analysis of a multicenter trial. Semin Thromb Hemostas 1991; 17: 343-346
• 14 Weber U, Koppenhagen K, Malzer H, Matthes M. Unterschiedliche Wirksamkeit von zwei Praparaten mit niedermolekularem Heparin bei Patienten mit elektivem Huftgelenksersatz. Langenbecks Arch Chir 1991; 376: 147-151
• 15 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625
• 16 Fareed J, Walenga JM, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann NY Acad Sci 1989; 556: 333-353